Himuka AM Pharma
himuka-am.com
Drug Discovery
Immunology & Inflammation Therapeutics
Prescription Drugs
Claim pageClaim
Follow
Overview
Connections
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
Betavc, Keio Innovation Initiative
Momentum
0/100
no fresh signals
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Alivexis is a technology-driven drug discovery company developing small-molecule therapeutics for oncology, chronic inflammation and immune…
Beeline Medicines is a clinical-stage biotechnology company developing precision therapies for autoimmune and inflammatory diseases, with…
Metagen Therapeutics is a Japanese biotech startup founded by researchers from Juntendo University, Keio University and Tokyo Institute of…
"We are committed to creating the future of oncology by developing innovative therapies inducing autophagy to address unmet medical needs".
Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Our approach enables selective modulation…
Luxna Biotech is a preclinical-stage Japanese biotechnology company that develops antisense oligonucleotide (ASO) therapeutics using novel…
Overview
Himuka AM Pharma develops drug candidates derived from adrenomedullin (AM), a bioactive peptide originally discovered at the University of Miyazaki. The company focuses on creating peptide derivatives and drug seeds intended to address unmet medical needs in vascular, inflammatory and organ-protective conditions. It is a Japanese biotechnology company developing AM-based therapeutics for clinical and pharmaceutical markets.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Keio Innovation InitiativeVia a fund
BetavcVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely